XML 51 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - AstraZeneca (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 22, 2016
Apr. 01, 2018
Jul. 02, 2017
Oct. 01, 2017
Dec. 31, 2016
Business Acquisition [Line Items]          
Goodwill [1]       $ 56,078 $ 54,449
AstraZeneca [Member]          
Business Acquisition [Line Items]          
Initial payment $ 552        
Additional payment made for a purchase price adjustment     $ 3    
Milestone payment     $ 50    
Deferred payment 175        
Maximum amount of potential milestone payments 75        
Maximum amount of potential sales-related payments $ 600        
Term of royalty payments 10 years        
Consideration transferred in business acquisition $ 1,045        
Payments for acquisitions, cash portion 555        
Contingent consideration assumed 490        
Identifiable intangible assets 879        
Other current assets 92        
Goodwill 92        
Deferred tax liabilities 17        
In Process Research and Development [Member] | AstraZeneca [Member]          
Business Acquisition [Line Items]          
Identifiable intangible assets 219        
Developed Technology Rights [Member] | AstraZeneca [Member]          
Business Acquisition [Line Items]          
Identifiable intangible assets 660        
Minimum [Member] | AstraZeneca [Member]          
Business Acquisition [Line Items]          
Undiscounted royalty payments 250        
Maximum [Member] | AstraZeneca [Member]          
Business Acquisition [Line Items]          
Undiscounted royalty payments $ 425        
Forecast [Member] | AstraZeneca [Member]          
Business Acquisition [Line Items]          
Milestone payment   $ 125      
[1] Amounts may not add due to rounding.